AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca said to have explored Bristol Myers merger | Fortune

AstraZeneca explored Bristol Myers acquisition ($133B), early-stage megadeal creating world's top-3 pharma player. Pharma consolidation signals M&A trend in regulated sectors; expect long compliance-driven tech integration, legacy interop complexity.